Posted by Michael Wonder on 25 Aug 2022
Ultomiris approved in Japan for the treatment of adults with generalised myasthenia gravis
25 August 2022 - First and only long-acting C5 complement inhibitor offers early onset and sustained efficacy, and has the potential to reduce treatment burden with dosing every 8 weeks.
Ultomiris (ravulizumab) has been approved in Japan for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive and whose symptoms are difficult to control with high dose intravenous immunoglobulin therapy or plasmapheresis.
